로딩 중…
StockDiggingStockDigging

Revvity, Inc.

RVTY· NYSE
$146.72+0.68%
2026-09-17

Financials

Valuation Metrics

Revvity, Inc.'s Market Cap is $16.37B. At end of 2025 it was $10.95B. Ranked #668 of 3,121 in US market (top 21%), #461 of 1,658 on NYSE (top 28%), #45 of 205 in Health Care Equipment & Services (top 22%) by Market Cap.

Investment Metrics(as of 2026-09-18)

MetricValue
Size
Market Cap$16.37B
Revenue$2.91B
Net Income$238M
Total Assets$12.05B
Net Assets$7.23B
Employees11,000
Value
P/E68.90x
P/B2.26x
P/S5.62x
EV/EBITDA24.36x
FCF Yield3.42%
Profitability
ROE3.29%
ROA1.97%
Op. Margin12.32%
Revenue Growth4.05%
Earnings Growth-17.07%
Financial Health
Debt Ratio66.64%
Total Debt$3.34B
FCF$559M
Cash$1.02B
Current Ratio1.80x
Net Debt/EBITDA3.02x
Dividend
Div. Yield0.19%
Div. Growth3.21%
Performance
1Y Return72.06%
1M Return28.98%
From 52W High-1.87%
1Y MDD-30.14%
Trading
Volume2,325,406 shares
Trading Value$342M
Per Share
EPS$2.13
BPS$64.80

Company Info

CEO Dr. Prahlad R. Singh Ph.D.
Employees 11,000
HQ Waltham, United States

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.